Technology ID
TAB-5036
Targeted Gene Mutation Technology for Studying Specific Cell Functions in Mice
E-Numbers
E-241-2017-0
Lead Inventor
Shevach, Ethan (National Institute of Allergy and Infectious Diseases (NIAID/NIH))
Co-Inventors
DeVico, Angela (National Institute of Allergy and Infectious Diseases (NIAID/NIH))
Development Stages
Pre-clinical (in vivo)
This technology includes the development of transgenic mice with a targeted gene mutation that flanks exon 8 of the Ikzf2 (Helios) gene using loxP sites. These Ikzf2 fl/fl (floxed) mice allow researchers to selectively delete the Ikzf2 gene in specific tissues or cells by crossing them with mice that express Cre recombinase under tissue-specific promoters. This approach provides a powerful tool for studying the role of the Helios gene in specific cells, which can be particularly useful in immunological research
Commercial Applications
The technology can be applied in the research of immunological functions, particularly in understanding the role of the Helios gene in immune cells. Additionally, it has potential applications in developing targeted therapies that require precise genetic modifications in specific cell types.
Competitive Advantages
This technology allows for precise gene deletion in targeted tissues or cells, avoiding the complications of whole-organism gene knockout. It offers a significant advantage in studying cell-specific functions without systemic effects.
Licensing Contact: